See what’s new.
Duke University ranks 24th worldwide for patents granted to academic institutions
Duke researchers are pioneering inventors and Duke is successfully commercializing these inventions for the benefit of the public.
Donald Patrick McDonnell, PhD, Wins 2025 Baxter Prize for Entrepreneurship
Professor Donald McDonnell (PCB, SOM) is a serial inventor with multiple commercialized technologies, including FDA-approved breast cancer drug ORSERDU.
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.
Duke Translational Chaperones help researchers secure over $6.5M in translational funding
In their pilot year, the new team at OTC worked with Duke life sciences PIs to position their research for maximal translational impact. Who will they help next?
Finding the right fit: inventive Duke students get crash course in commercializing their technologies
Making customer calls and polishing pitches – Duke’s innovation ecosystem collaborates to offer Duke graduate and professional students a hands-on technology commercialization bootcamp.
Dr. Jim Flatt Announced as New CEO of DMC Biotechnologies
DMC Technologies is a Duke start-up commercializing sustainable chemistry technology out of the lab of Associate Professor Michael Lynch (BME, Pratt).
Interdisciplinarity and impact shine at Duke Research and Innovation Summit 2025
The annual gathering of the Duke research community emphasized how innovators are making an impact through their research.
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
Tavros Therapeutics was co-founded by Eoin McDonnell, graduate of the Duke University Molecular Cancer Biology PhD Program, and Associate Professor Kris Wood (Pharmacology and Cancer Biology, SOM).